Tareq A Juratli

Summary

Country: Germany

Publications

  1. Juratli T, Stasik S, Zolal A, Schuster C, Richter S, Daubner D, et al. TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study. Clin Cancer Res. 2018;24:5282-5291 pubmed publisher
    ..Further studies are needed to complement the findings of our exploratory analysis. Clin Cancer Res; 24(21); 5282-91. ©2018 AACR. ..
  2. Juratli T, Engellandt K, Lautenschlaeger T, Geiger K, von Kummer R, Cerhova J, et al. Is there pseudoprogression in secondary glioblastomas?. Int J Radiat Oncol Biol Phys. 2013;87:1094-9 pubmed publisher
    ..Our results highlight the differences between primary glioblastomas and sGBM in particular as they relate to PP. ..
  3. Juratli T, Stephan S, Stephan A, Sobottka S. [Acute treatment of patients with severe traumatic brain injury]. Anaesthesist. 2015;64:159-74 pubmed publisher
    ..The prehospital decision to intubate must be made on a case by case basis at the accident site. A level I trauma center should be the destination for this patient group. ..
  4. Juratli T, Lautenschläger T, Geiger K, Pinzer T, Krause M, Schackert G, et al. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients. J Neurooncol. 2015;124:197-205 pubmed publisher
    ..This retrospective long-term study demonstrates that RT and CT (mostly PCV) significantly improves progression-free and overall survival in IDH-mutant secondary high-grade astrocytoma patients, regardless of 1p/19q-codeletion status. ..
  5. Juratli T, Geiger K, Weigel P, von der Hagen M, Daubner D, Pinzer T, et al. A five year-old child with clear cell petro-clival meningioma: case report with clinical and histopathological long-term follow-up. Childs Nerv Syst. 2015;31:2193-8 pubmed publisher
    ..Further evaluation of these growth factors in clear cell meningioma is required to establish the optimal treatment of these aggressive tumors. ..
  6. Seidlitz A, Siepmann T, Löck S, Juratli T, Baumann M, Krause M. Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme. Radiat Oncol. 2015;10:172 pubmed publisher
    ..Although this study was limited by its retrospective nature, its results indicate that short delays of postoperative radiochemotherapy, e.g. for screening of a patient for a clinical trial, may be uncritical. ..
  7. Perrakis A, Juratli T, Hohenberger W, Croner R, Schackert G. [Surgery for metastases, anatomical and ethical limits. Special aspect: oligometastases]. Chirurg. 2016;87:208-15 pubmed publisher
  8. Juratli T, Kirsch M, Robel K, Soucek S, Geiger K, von Kummer R, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J Neurooncol. 2012;108:403-10 pubmed publisher
    ..The presence of IDH mutations fails to demonstrate a significant influence on survival in the multivariate analysis of LGA patients. Early RT appears to be beneficial only LGA patients with IDH-mutations. ..
  9. Juratli T, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol. 2012;110:325-33 pubmed publisher
    ..In addition, IDH mutations are a more powerful prognostic marker concerning both PFS and MS than the MGMT promoter status in those patients. ..

More Information

Publications12

  1. Juratli T, Peitzsch M, Geiger K, Schackert G, Eisenhofer G, Krex D. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. Neuro Oncol. 2013;15:682-90 pubmed publisher
    ..Although intratumoral 2-hydroxyglutarate accumulation provides a marker for the presence of IDH mutations, the metabolite is not a useful biomarker for identifying malignant transformation or evaluating malignant progression. ..
  2. Juratli T, Schackert G, Krex D. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches. Pharmacol Ther. 2013;139:341-58 pubmed publisher
    ..Thus, we have to learn from our mistakes in the past and we strongly encourage future developments in this field. ..
  3. Juratli T, Klein J, Schackert G. [Chronic subdural hematoma in the elderly]. Chirurg. 2017;88:131-135 pubmed publisher
    ..Controlled trials need to be carried out to determine whether pharmacological therapies can also be beneficial in addition to surgical treatment. ..